/AI Therapeutics
Invite

Pending to review

Not sure yet

Interested

Not interested

Get more companies

Download list

Company
Fit assessment
Description
Subspaces
HQ Location
Founded
Employees
Total Funding Raised
Funding Status
Received on
Picks for your space

Silicosome leverages machine learning for drug design, discovers patterns in biological data, and develops new therapeutics, including biomarker identification.

  • Biomarker Identification
United States11 - 50NA
1 year ago

Orikami leverages machine learning and data analysis to develop digital biomarkers, enhancing therapeutic options and personalizing healthcare for chronic disease management.

Orikami is a Dutch MedTech organization specialized in applied data science and development and implementation of digital biomarkers to enable personalized healthcare for people with chronic diseases. With a team of data scientists and researchers we are on a mission to improve 100 million lives before 2030 by access to personalized healthcare. We believe health data is underutilized. We use real world patient data to enable personalized healthcare paths for our clients to improve outcomes, quality of life and affordable healthcare. Therefore we develop digital biomarkers. Digital biomarkers are defined as objective, quantifiable physiological and behavioural data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The collected data is typically used to monitor, explain, influence and/or predict health-related outcomes. Advanced analytics, machine learning, artificial intelligence: developments in the field of decision-making based on data analysis are moving fast. Data in healthcare matters!
  • Biomarker Identification
Nijmegen (Netherlands)201111 - 50$659.06KSeed, $659.06K, October 9, 2019
1 year ago